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It is controversial whether dietary fiber protects against colorectal cancer because of conflicting 
results from human epidemiologic studies. However, these studies and mouse models of colorectal 
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cancer have not controlled the composition of gut microbiota, which ferment fiber into short-chain 
fatty acids such as butyrate. Butyrate is noteworthy because it has energetic and epigenetic 
functions in colonocytes and tumorsuppressive properties in colorectal-cancer cell lines. We 
utilized gnotobiotic mouse models colonized with wild-type or mutant strains of a butyrate-
producing bacterium to demonstrate that fiber does have a potent tumor-suppressive effect but in a 
microbiota- and butyrate-dependent manner. Furthermore, due to the Warburg effect, butyrate was 
metabolized less in tumors where it accumulated and functioned as an HDAC inhibitor to 
stimulate histone acetylation and affect apoptosis and cell proliferation. To support the relevance 
of this mechanism in human cancer, we demonstrate that butyrate and histone-acetylation levels 
are elevated in colorectal adenocarcinomas compared to normal colonic tissues.
INTRODUCTION
It is highly controversial whether dietary fiber protects against colorectal cancer (CRC) 
because of conflicting results from human cohort-based epidemiologic studies (1-5). These 
studies have been complicated by the participants’ genetic heterogeneity, differences in the 
composition of their gut microbiota, and the utilization of different fiber sources (6-8). It 
also has not been established how dietary fiber might protect against CRC, but two general 
mechanisms have been proposed that are not mutually exclusive. First, insoluable fiber 
bulks luminal contents and may speed colonic transit to minimize the exposure of the 
colonic epithelium to ingested carcinogens such as nitrosamines from charred meat. Second, 
bacteria in the lumen of the colon ferment soluable fiber into short-chain fatty acids 
(SCFAs) and other metabolites with potentially beneficial properties. Butyrate is an 
abundant (up to >10 mM) SCFA that is transported into the colonic epithelium and localizes 
within two subcellular compartments (9,10). It undergoes β-oxidation inside the 
mitochondria and accounts for ≥70% of the energy used by normal colonocytes (11), and it 
also functions as a histone deacetylase (HDAC) inhibitor inside the nucleus to epigenetically 
regulate gene expression (12). Butyrate is a plausible candidate for tumor suppression 
because it inhibits cell proliferation and induces cell differentiation or apoptosis when added 
to tumor-derived cell lines (9,10). However, butyrate can also have contradictory effects 
(13,14), and it is crucial that we move beyond “factor dump” experiments where relatively 
high doses of butyrate are added to CRC cell lines. It must be demonstrated that dietary fiber 
and gut microbiota can modulate butyrate levels in the colonic lumen, and that this, in turn, 
can inhibit colorectal tumorigenesis in vivo where the colonic crypt architecture is intact and 
functions in the presence of stromal cells.
RESULTS
Our experiments were designed to test the hypothesis that dietary fiber protects against CRC 
in a microbiota- and butyrate-dependent manner (Supplementary Fig. S1). To control the 
genetics and microbiota in our experiments, we maintained a colony of BALB/c inbred mice 
polyassociated with 4 commensal bacteria [a subset of the altered Schaedler flora or ASF 
(15)] plus or minus the butyrate-producing bacterium Butyrivibrio fibrisolvens (16) in 
gnotobiotic isolators (Supplementary Figs. S1 and S2). These mice were provided low- or 
high-fiber (6% fructo-oligosaccharide/inulin) diets that were otherwise identical and 
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calorically matched (Supplementary Figs. S1 and S3). As expected, mice colonized with the 
ASF plus B. fibrisolvens that were also provided high-fiber (“prebiotic”) diets (herein 
referred to as the experimental group) had significantly higher luminal butyrate levels than 
the other 3 groups of mice (herein referred to as the control groups) based on LC-MS 
measurements (Supplementary Fig. S4). This difference was not observed for acetate or 
propionate, which are the other two major SCFAs (Supplementary Table 1). We treated 
these mice with azoxymethane (AOM) and dextran sodium sulfate (DSS) to induce CRC 
and analyzed them 5 months later (17). Following 1 injection of AOM and 2 cycles of DSS, 
the experimental group had significantly fewer tumors than each control group. The 
experimental group had a mean of 1 tumor per mouse, whereas the control groups had 3-4 
tumors per mouse (Fig. 1A). These results indicate that neither B. fibrisolvens nor high fiber 
had a protective effect on their own, whereas they did have a protective effect when 
combined.
Next, we treated mice with 5 injections of AOM and 3 cycles of DSS, which increased the 
tumor incidence and multiplicity as expected (Fig. 1B). More importantly, the B. 
fibrisolvens and high-fiber diet still had a protective effect in combination (3 tumors per 
mouse), but not in isolation (8-11 tumors per mouse) (Fig. 1B). The experimental group also 
had significantly smaller (Fig. 1C) and less advanced (Fig. 1D-E) tumors based on their 
histopathologic characteristics (18). Tumors from the experimental and control groups had 
β-catenin gain-of-function mutations (Supplementary Fig. S5A-S5C) and were positive for 
nuclear β-catenin staining (Supplementary Fig. S6), which indicates that the mechanism of 
tumor initiation was due to aberrant Wnt signaling. These findings were expected based on 
previous AOM studies and confirm that the mechanism of tumor initiation is similar to 
human CRC (17). For the 5 AOM/3 DSS dose regimen, we also identified squamous cell 
tumors derived from the surface ectoderm or glandular epithelium of the peri-anal region 
rather than the colonic mucosa (Supplementary Fig. S7A-S7B). In contrast to the colorectal 
tumors, the incidence, size, and histopathologic progression of the squamous tumours were 
not significantly different between the experimental and control groups (Supplementary Fig. 
S7A-S7B). Therefore, the squamous tumors, which are known to occur in the AOM/DSS 
model (17), served as an internal control. They demonstrate that mice from the different 
treatment groups received the same exposure to carcinogen, as expected, and that the tumor-
suppressive effect of the fiber-microbiota-butyrate axis is specifically localized to the 
colonic mucosa and does not influence tumor formation outside of the lumen even at nearby 
sites. This dichotomy is compatible with the bioavailability of butyrate being primarily 
restricted to the colonic mucosa (9,10).
To confirm that the tumor-suppressive mechanism for B. fibrisolvens and high fiber is due to 
butyrate production, we exploited a mutant B. fibrisolvens strain with a 0.8-kb deletion in 
the butyryl-CoA synthesis operon (16) that produces ≤5-fold less butyrate when cultured 
(19) (Supplementary Fig. S8A-S8C). To validate this deficiency in butyrate production, we 
cultured the mutant and wild-type B. fibrisolvens strains in media supplemented with fructo-
oligosaccharides/inulin (the same fiber source provided to the mice) and observed 7-fold 
lower butyrate levels in the media from mutant cultures compared to wild-type cultures 
(Supplementary Fig. S8A-S8C) Next, we colonized BALB/c mice with ASF plus the mutant 
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B. fibrisolvens strain and evaluated AOM/DSS-induced tumorigenesis. These microbiota 
combined with a high-fiber diet conferred an attenuated protective effect with significantly 
more tumors than mice colonized with the wild-type bacterium (Fig. 1B). The mutant B. 
fibrisolvens combined with a high-fiber diet also had a diminished protective effect on tumor 
size and progression (Fig. 1C-E). These results demonstrate that bacterial butyrate 
production is commensurate with the tumor-suppressive effect. As an additional control, we 
colonized BALB/c mice with ASF only (in the absence of wild-type or mutant B. 
fibrisolvens) and provided them a tributyrin-fortified diet, which increases colonic butyrate 
levels in a microbiota-independent manner (20) (see Supplementary Fig. S3 for the 
formulation of this diet and the salient attributes of tributyrin and Supplementary Fig. S4 for 
luminal butyrate levels in these mice). Following the 5 AOM/3 DSS dose regimen, these 
mice had fewer (mean of 2) colorectal tumors than any other treatment group (Fig. 1B). 
These tumors were small and low grade similar to the previous experimental group (Fig. 1C-
E). Therefore, exogenous butyrate recapitulated the tumor-suppressive effect of wild-type B. 
fibrisolvens and high fiber. Taken together, these results demonstrate unequivocally that 
butyrate is a causative factor in the tumor-suppressive mechanism.
Our previous analysis of cell-culture models suggested that the molecular mechanism of 
tumor suppression might involve metabolic differences between normal and cancerous 
colonocytes (21,22). Unlike normal colonocytes, which utilize butyrate as their primary 
energy source (11), CRC cells primarily rely on glucose and undergo increased glycolysis 
with a concomitant decrease in mitochondrial oxidative metabolism because of the Warburg 
effect (23). Consequently, butyrate is not metabolized inside of mitochondria to the same 
extent and accumulates as an HDAC inhibitor in CRC cells (22). To test the validity of this 
model in vivo, we confirmed that tumors dissected from our gnotobiotic mice exhibited 
certain characteristics of the Warburg effect such as increased expression of lactate 
dehydrogenase A (LDHA) (Fig. 2A-B) and other markers (Supplementary Fig. S9A-S9C). 
Furthermore, compared to normal colonic tissue, the tumors produced increased levels of 
lactate (, which is a glycolytic end product that is catalyzed by LDHA and known to be 
elevated in cancer cells undergoing the Warburg effect. Based on LC-MS measurements, 
butyrate levels were significantly higher inside of tumors than normal colonic tissue (Fig. 
2D-E). To investigate the basis for this difference, we performed flux experiments that 
measured butyrate oxidation. Consistent with the Warburg effect and our previous analysis 
of cell-culture models, butyrate oxidation was significantly diminished in tumors compared 
to normal colonic tissues (Supplementary Fig. S10A-S10E). We also analyzed several 
monocarboxylate transporters (MCTs) responsible for butyrate influx, but they did not show 
consistent expression differences between tumors and normal colonic tissues 
(Supplementary Fig. S10A-S10E). These findings suggest that butyrate accumulates in 
tumors because of diminished oxidation rather than increased uptake.
The butyrate concentration inside tumors from mice in the experimental treatment groups 
was calculated to be >100 μM, which is consistent with it acting as an HDAC inhibitor 
based on its IC50 (24). Therefore, we performed immunohistochemistry (IHC) to analyze 
pan-histone 3 acetylation (H3ac) levels. H3ac levels were markedly higher in tumor cells 
than normal adjacent colonocytes (Fig. 2F). Because the tumor cells and normal colonocytes 
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were present in close physical proximity on the same slide, our IHC experiments were 
internally controlled. These results were confirmed by western blot analyses (Fig. 2G), and 
quantification demonstrated H3ac levels were significantly higher in tumors from the 
experimental groups compared to grade-matched tumors from the control groups (Fig. 2H). 
The observed differences in H3ac were inversely correlated with significant differences in 
HDAC activity (Fig. 2I), which is compatible with butyrate functioning as an HDAC 
inhibitor.
Butyrate can induce histone acetylation and expression of pro-apoptotic genes such as FAS 
and cell-cycle regulators such as p21 and p27 to stimulate apoptosis and inhibit proliferation 
in CRC cell lines (10). Therefore, we performed quantitative ChIP assays and RT-qPCR to 
evaluate promoter H3ac levels and mRNA levels of these genes. H3ac and mRNA levels 
were significantly higher in tumors from experimental mice than control mice, which, in 
turn, were significantly higher than normal colonic tissues (Fig. 3A-F). Furthermore, cleaved 
caspase 3 assays and Ki-67 assays demonstrated that the experimental tumors exhibited 
increased apoptosis and decreased cell proliferation (Fig. 3G-H and Supplementary Fig. 
S11). These results provide insight into gene targets and the cell biological basis of the 
tumor-suppressive effect.
To provide support for the relevance of the proposed molecular mechanism in human tumor 
suppression, we analyzed human colorectal adenocarcinomas and adjacent macroscopically 
normal mucosa (see Supplementary Table 2 for clinical information). We detected 
significantly elevated levels of butyrate (Fig. 4A-B) and H3ac (Fig. 4C-D) in the 
adenocarcinomas compared to the macroscopically normal mucosa samples. Although these 
clinical samples were obtained from two different medical centers, there was a high level of 
concordance between them (Fig. 4B).
DISCUSSION
The findings presented here strongly support the hypothesis that dietary fiber protects 
against CRC. Our data support a general mechanism that includes microbial fermentation of 
fiber rather than fiber exclusively speeding colonic transit to minimize the exposure of 
colonocytes to ingested carcinogens. Our data also support a molecular mechanism where 
microbial fermentation of fiber yields butyrate, which serves as the preferred energy source 
of normal colonocytes and supports homeostasis (11,25) but accumulates in cancerous 
colonocytes due to the Warburg effect and functions as an HDAC inhibitor to inhibit cell 
proliferation and stimulate apoptosis (21,22) These general and molecular mechanisms are 
depicted as a final working model in Fig. 4E.
Butyrate may have additional effects independent of HDAC inhibition in tumor suppression. 
For example, both fiber and butyrate can be metabolized by certain clades of bacteria, and 
this can influence the microbiome and host metabolism (26). Butyrate is also a ligand for 
certain G-protein-coupled receptors (GPRs) and has anti-inflammatory effects (9,10), which 
include the ability to induce the differentiation and expansion of immunosuppressive 
regulatory T (Treg) cells (27-30). However, we did not observe a significant difference in 
the number of Treg cells (Supplementary Fig. S12A-S12E) or the abundance of associated 
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cytokines such as IL-10 (Supplementary0 Fig. S13) based on flow-cytometry and cytokine-
profiling experiments, respectively. In fact, there was minimal inflammation in our 
gnotobiotic models following DSS or AOM/DSS treatments (Supplementary Figs. S12-14A-
C), which was a consequence of our experimental design. In order to rigorously control 
butyrate levels, our gnotobiotic mice were colonized with 4-5 commensal bacteria that have 
not been implicated in inflammation (including 2 Lactobacillus species), and they were 
unable to induce a robust inflammatory response. We know that this is the case based on 
control experiments where we transferred a subset of our AOM-treated gnotobiotic mice to a 
specific pathogen free (SPF) facility where they became “conventionalized” with diverse 
microbiota. When these conventionalized mice were subsequently treated with DSS in the 
SPF facility, the inflammatory response was markedly more severe and the tumor burden 
was >10-fold higher than the same AOM-treated mice that received an identical DSS 
treatment while still maintained in gnotobiotic isolators (Supplementary Fig. S15). Butyrate 
is an agonist for at least one GPR (GPR109A) expressed on the apical surface of 
colonocytes that can mediate butyrate tumor-suppressive effects (30,31). Although our data 
support a model where butyrate enters tumor cells via MCTs to inhibit HDACs (Fig. 4E), 
butyrate could also be activating GPR109A signaling. We did not detect significant 
differences in the expression of Il18 (Supplementary Fig. S16), which is a GPR109A target 
gene in the colonic epithelium that is relevant to tumor suppression (30), although this does 
not exclude a role for GPR109A or other GPRs.
Our gnotobiotic mouse model was polyassociated with several species of bacteria and 
provided a homogeneous diet that included a single type of fiber. This reductionist approach 
was necessary to demonstrate that fiber protects against CRC and interrogate butyrate 
function. However, it does not reflect the complex microbiota that exist within the human GI 
tract or our more varied diets that include multiple sources of fiber. Other bacterial 
metabolites undoubtedly participate in tumor suppression but were beyond the scope of our 
study. Nevertheless, it is tempting to speculate that many of the conclusions drawn from our 
mouse model are relevant to human health as discussed below.
As human populations have shifted away from traditional, high-fiber diets towards 
processed foods containing less complex carbohydrates and more refined sugars, CRC 
incidence has increased markedly. Yet the link between fiber and CRC prevention has been 
tenuous because of conflicting results from cohort-based epidemiologic studies. By 
rigorously controlling genetics, the composition of gut microbiota, and other dietary factors 
such as fat that may mask a beneficial fiber effect, we can conclude from this study that 
fiber does, in fact, protect against colorectal tumorigenesis. An important aspect of this work 
is the central role of gut microbiota and the fermentation product butyrate. Consequently, we 
propose that cohort-based epidemiologic studies should be revisited and integrated with 
microbiome studies. We predict that if microbiome differences of participants were taken 
into account, then it would be possible to discriminate between those individuals who 
respond to the anticancer chemoprotective effect of fiber from non-responders. This would 
resolve some of the conflicting results from previous human studies and possibly confirm 
butyrate as an important molecule in human chemoprotection. This idea is supported by 
several microbiome studies that have reported fewer butyrate-producing bacteria in human 
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colorectal cancer cases than controls even without diet being taken into consideration 
(32-36).
Metagenomic sequencing projects have made a number of observations regarding the 
microbiome and the incidence of certain cancers. However, these studies are correlative so it 
is difficult or impossible to know whether the microbiome differences are a cause or a 
consequence of the disease state. In contrast, relatively few studies have investigated the 
function of microbiota in gnotobiotic mouse models of cancer (37,38). Furthermore, most or 
all of these studies have focused on bacteria that promote oncogenesis by causing 
inflammation or genotoxicity (37,38). In contrast, butyrate-producing bacteria confer a 
tumor-suppressive effect, which arguably has greater translational potential for 
chemoprevention via probiotics or prebiotics.
The molecular mechanism described here involves butyrate functioning as an HDAC 
inhibitor, which is noteworthy because synthetic HDAC inhibitors are being used as 
anticancer chemotherapeutic agents with some having already received FDA approval and 
others being evaluated in phase 3 clinical trials (4). The translational implication of our 
model is attractive because diet (prebiotics-fiber) and possibly microbiota supplementation 
(probiotics-butyrate-producing bacteria) modulate the levels of an endogenous HDAC 
inhibitor (butyrate) for the purpose of chemoprevention. This approach has several 
advantages compared to the systemic delivery of synthetic HDAC inhibitors for 
chemotherapy (4). First, it should be easier to modulate the epigenome and transcriptome 
profiles of cells at an early stage of tumorigenesis; later-stage tumor cells are more likely to 
have accumulated mutations or epimutations that make them refractory to HDAC inhibition. 
Second, because the bioavailability of butyrate is primarily restricted to the colon, it will not 
have adverse effects in other tissues. Third, unlike synthetic HDAC inhibitors, butyrate is a 
naturally occurring fatty acid readily metabolized by normal cells so it does not have 
adverse effects even in the colon. The ability of butyrate to specifically target tumor cells in 
the colon is due to the Warburg effect (22). Because cancerous colonocytes rely on glucose 
as their primary energy source, butyrate is not metabolized in the mitochondria to the same 
extent and is able to accumulate as a tumor-suppressive metabolite (analogous to the 
oncometabolite 2-hydroxyglutarate) in the nucleus where it functions as an HDAC inhibitor 
to stimulate histone acetylation, induce apoptosis, and inhibit cell proliferation.
METHODS
Mice
BALB/c mice were maintained in isolators (Class Biologically Clean, Madison, WI) and 
bred in house at the National Gnotobiotic Rodent Resource Center (NGRRC) at the 
University of North Carolina at Chapel Hill. All mouse experiments were approved by the 
Institutional Animal Care and Use Committees (IACUC) review board at the University of 
North Carolina at Chapel Hill and were performed in accordance with federal guidelines.
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Food, water, and all other materials including cages and bedding were autoclaved and 
imported into the isolators using aseptic technique following standard procedures. Each diet 
was from Test Diet (Richmond, IN). The low-fiber diet (5SRZ, Cat. No. 1813680) contained 
2% cellulose while the high-fiber diet (5SVL, Cat. No. 1813901) contained 2% cellulose 
plus 6% fructo-oligosaccharide/inulin (Sigma-Aldrich #F8052 and 12255, St. Louis, MO). 
The tributyrin diet (5AVC, Cat. No. 1814961) contained 2% cellulose plus 6% tributyrin 
(Sigma-Aldrich #W222305). The initial colonization of germfree BALB/c mice with 
specific bacteria (which were the only imported materials not autoclaved except filter-
sterilized AOM/DSS) was performed by oral gavage following standard procedures.
Bacteria
Bacteria were cultured in BBL Schaedler broth containing vitamin K (Cat. No. 221541) that 
was supplemented with 5% FBS in an anaerobic chamber (ThermaForma) filled with an 
anaerobic mixture (Airgas #750333 consisting of 5% CO2 and 10% H2 balanced with N2) at 
37°C. For experiments measuring butyrate production in culture, the Schaedler broth was 
supplemented with 0.5% or 5% FOS/inulin (the same additive that was used for the high-
fiber mouse diet). The following bacteria were cultured: ASF360 (Lactobacillus 
acidophilus), ASF 361 (Lactobacillus salivvarius), ASF457 (Flexistipes phylum), and 
ASF519 (Bacteroides distasonis), which were obtained from Taconic, and Butyrivibrio 
fibrisolvens (type I, ATCC 19171; type II, ATCC 51255) obtained from ATCC.
AOM/DSS
AOM (Sigma-Aldrich #A5486) was dissolved in PBS at a concentration of 50 mg/mL and 
stored as aliquots at -80°C. Aliquots were subsequently thawed and diluted in sterile saline 
(0.9% NaCl) at a concentration of 1.25 mg/mL. This final AOM solution was then filter 
sterilized in a tissue-culture hood, imported into gnotobiotic isolators, and delivered by i.p. 
injection at a final concentration of 10 mg per kg body weight. AOM injections were 
performed on a weekly basis for a total of up to 5 injections. 5 days after the final AOM 
treatment, the mice were provided drinking water containing 2.5% DSS (ICN, MW 36-50 
kDa) for 5 days. The DSS-containing water was then replaced by normal drinking water for 
16 days. This cycle was repeated 1 or 2 more times resulting in either 2 or 3 DSS treatments. 
The DSS was prepared by dissolving it in autoclaved water followed by filter sterilization in 
a tissue-culture hood and importation into gnotobiotic isolators.
Scoring of Tumors
Tumor scoring was performed in a blinded manner by two veterinary pathologists. Colons 
were flushed and then splayed open. Colonic mucosal masses counted as tumors grossly 
appeared as variably sized, irregular, asymmetrical, shiny to roughened, tan to red, sessile to 
pedunculated, occasionally coalescing nodular masses. For coalescing tumors, the number of 
individual tumors was estimated. Colonic mucosal masses considered lymphoid nodules and 
not included in the tumor count were approximately 0.5 cm in diameter, 0.2 cm in height, 
and grossly appeared as symmetrical, shiny, translucent, flat, plaque-like masses.
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Swiss-rolled colons and other tissues (e.g., lymph nodes and liver) were fixed in 4% 
paraformaldehyde or 10% formalin and processed for the production of 5-micron paraffin 
sections. Sections were stained with hematoxylin and eosin (H&E) or processed for IHC 
using standard procedures. Antibodies included pan-acetyl H3 (Millipore #06-599), total H3 
(Millipore #05-928), LDHA (Cell Signaling #3582), Cleaved Caspase-3 (Asp175) (Cell 
Signaling #9661), and Ki-67 (Abcam #15580). IHC quantification was performed using 
Image J to count the number of normal colonic epithelial cells or tumor cells that were 
positive for Cleaved Caspase-3 and hematoxylin in randomly selected crypts. The cleaved 
caspase-3 positive cells were identified by their distinctive brown cytoplamic staining. The 
number of cleaved caspase-3 cells counted per crypt was divided by the total number of 
hematoxylin-stained cells counted in the exact same crypt. At least 10 randomly selected 
normal crypts or tumorigenic crypts were quantified per animal times 5 animals per 
treatment group (i.e., biological replicates). A similar approach was done for Ki-67 and 
H3ac except the H3ac results were normalized to total H3.
Sample Acquisition
After each mouse was sacrificed, colons were removed starting at a point immediately distal 
to the junction between the cecum and the ascending colon and ending at the anus. The 
entire colon was splayed open, and luminal contents were removed from the proximal third 
of the colon for LC-MS experiments. Fecal pellets were not used as proxy for luminal 
contents. After luminal contents were removed, colons were rinsed twice in PBS. 
Macroscopically normal colonic tissue and tumors were dissected for LC-MS experiments 
and other experiments (e.g., western blots, HDAC activity assays, ChIP, RT-qPCR, flux 
experiments). Tumor dissections were performed to minimize the amount of normal 
adjacent tissue.
LC-MS
For detection of butyrate, samples were treated with 13C1 or 13C4-butyrate (Isotech 
#292656) at a final concentration of 10 mM (as an internal control to assess recovery 
efficiency and as a standard to calculate endogenous butyrate levels) and then homogenized 
in 0.1% ammonium hydroxide. Macromolecules were removed by centrifugation of lysates 
through 3-kDa spin-filters (Pall Corporation, Cat. #OD003C33). Flow-throughs were then 
analyzed for exogenous (13C4) and endogenous (12C4) butyrate by HPLC separation with 
subsequent detection by an Agilent 6520 AccurateMass Q-TOF mass spectrometer operating 
in negative mode (Santa Clara, CA). Peak areas were calculated using MassHunter 
Workstation software. Chromatographic peaks were integrated for samples and areas were 
compared to peak area for standards (10 mM) for each compound. For detection of other 
SCFAs, the procedure was the same except the appropriate 13C4-labeled acetate and 
propionate were used as standards.
Western Blot Analyses
Western blots were performed following standard procedures, and antibodies that were used 
included pan-acetyl H3 (Millipore #06-599), total H3 (Millipore #05-928), LDHA (Cell 
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Signaling #3582), α-tubulin (Sigma-Aldrich #T6793), P-AKT (Ser473) (Cell Signaling 
#4060), total AKT (Cell Signaling #2965), and P-PDH (Ser293 of E1α isoform)
(Calbiochem #AP1062).
HDAC Assays
Nuclear extracts were prepared from frozen tissues using a kit (Sigma #NXTRACT) dounce 
homogenization. HDAC colorimetric assays were performed using a kit (Epigentek 
#P-4034). HDAC activities were normalized to protein levelsfor each sample.
RT-qPCR
RNA was prepared using Trizol reagent (Invitrogen) and reverse transcribed using random 
hexamers and SuperScript II RT (Invitrogen) according to standard procedures. 20 μl 
reactions that included 10 μl of either 2× TaqMan or 2× Power SYBR Green master mix 
(Applied Biosystems) with 50-100 ng of cDNA and the appropriate primers (all assays were 
previously published) were run on an ABI 7300 instrument. Product accumulation was 
monitored by FAM or SYBR Green fluorescence. Control reactions lacking reverse 
transcriptase yielded very low to no signal. Relative expression levels were determined 
using the ΔΔCt method and normalized to Gapdh.
ChIP Assays
Tissues were pulverized in liquid nitrogen using a mortar and pestle and then crosslinked in 
pre-warmed 0.4% formaldehyde in PBS for 10 minutes at 37°C. The crosslinking reaction 
was stopped by adding glycine to a final concentration of 0.125 M and then sonicated with 
four 10-sec pulses at 30% of maximum power. IP dilution buffer (0.01% SDS, 1.1% Triton 
X-100, 1.2 mM EDTA, 16.7 mM Tris at pH 8.1, 167 mM NaCl, protease inhibitors) was 
added, 5% of the volume was removed and used as input while the remainder was incubated 
overnight at 4°C with the appropriate antibody: pan-acetyl H3 (Millipore #06-599), total H3 
(Millipore #05-928), or rabbit IgG (Santa-Cruz) as a negative control. Protein A/G agarose 
beads (Santa Cruz) were added and incubated for at least 2 h at 4°C, and then washed and 
eluted according to standard procedures.
qPCR was performed using Power SYBR Green Master Mix (Applied Biosystems (Applied 
Biosystems) on an ABI 7300 instrument under default cycling conditions (95°C 15 sec 
followed by 60°C 1 min for 45°C cycles). Dissociation curves and agarose gels 
demonstrated a single PCR product in each case without primer dimers. Relative enrichment 
was determined from a standard curve of serial dilutions of input samples.
Flux Experiments
~1×106 cells were incubated inside Exetainer breath storage tubes (Labco Limited) in 1 mL 
of PBS containing 0.5 mM 13C1-butyrate and 5 mM 12C-glucose for 1 hr at 37°C. Reactions 
were stopped with sodium azide treatment. Butyrate oxidation was assessed by analyzing 
isotopic CO2 derived from butyrate to non-isotopic CO2 derived from glucose using a 20/20 
gas isotope ratio mass spectrometer (Europa Scientific) at Metabolic Solutions (Nashua, 
NH). Dissolved CO2 in solution was liberated into the tube headspace by the addition of 100 
μL of saturated citric acid. The ratio of 13CO2 to 12CO2 (mass 45 to 44) was measured 
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directly from the sample tube headspace. All samples were compared to an internal 
reference gas (5% CO2, balance 75% N2 and 20% O2) that had been calibrated against the 
International standard PeeDeeBelmnite (PDB). The results were expressed as %13C 
= 13CO2 / (13CO2 + 12CO2) and normalized to normal colon. The analytical precision of the 
instrument is 0.0001 atom % 13C.
Fetal Human Colonocytes (FHC) and HCT116 cells were obtained from ATCC and split 
into Seahorse 24-well cell culture plates seeded at 20k cells per well. The next day the 
normal growth media for each cell was replaced with fatty acid oxidation media, which 
contains 110 mM NaCl, 4.7 mM KCl, 2 mM MgSO4, 1.2 mM Na2HPO4, 0.5 mM, and 2.5 
mM glucose adjusted to a pH of 7.4. FHC and HCT116 cells were incubated in this media 
for 1 hr in a non-CO2 incubator at 37°C and then run on the XF24 Analyzer (Seahorse 
Bioscience, North Billerica, MA) After three baseline measurements of the oxygen 
consumption rate (OCR) butyrate was injected into each well. 6 more OCR measurements 
were then made and 2DG (final concentration of 5 mM) was injected into each well. 6 more 
OCR measurements were then made. OCR was then suppressed by injecting 10% sodium 
azide into each well. Contribution of butyrate oxidation to OCR was determined after 
injection of 2DG, which inhibited glucose oxidation, and before sodium azide treatment.
Flow Cytometry
Colonic epithelial cells were isolated by incubating splayed-open colons in PBS containing 
5 mM EDTA at 37°C. After a 30-minute incubation while being rotated, the colonic tissue 
was transferred to a new tube for the isolation of lamina propria cells, and the epithelial cells 
were pelleted and washed. Lamina propria cells were isolated by incubating the colonic 
tissue minus the delaminated epiethelial cells in pre-warmed 0.5 mg/mL Collagenase Type 4 
(Worthington #LS004186) in 1X PBS with DNAse. Samples were rotated at 37°C for 20 
minutes, filtered through a 40-μm cell strainer and repeated twice more. After pre-digest and 
digest steps, collected cells were immediately washed in PBS containing 2% FBS and kept 
at 4°C to maintain viability. The colonic epithelial cells and lamina propria cells were then 
combined. These cells as well as single-cell suspensions from spleens were stained for flow 
cytometric analysis using a cocktail of PE-Texas Red anti mouse CD11c (clone N418) from 
Molecular Probes, PerCP anti-mouse CD45R [B220] (RA3-6B2) from BioLegend, and 
AF488 anti-mouse CD4 (GK 1.5), PE anti-mouse CD69 (H1.2F3), PE-Cy7 anti-mouse Gr-1 
(RB6-8C5), eF450 anti-mouse CD11b (M1/70), APC anti-mouse CD8α (53-6.7), and APC-
eF780 anti-mouse CD45 [Leukocyte common antigen] (30-F11), all from eBioscience. A 
separate set of reactions was used to detect Treg cells using a kit from eBioscience 
(#88-8118-40). Stained samples were read on a CyAn cytometer (Dako Cytomation), and 
the listmode files analysed with the Summit Software package from Beckman-Coulter. 
Abbreviations for this section: PE, phycoerythrin; AF488, Alexa fluor 488; APC, 
allophycocyanin; PerCP, Peridinin-chlorophyll-protein complex.
Luminex-Based Cytokine Profiling
In order to measure cytokine and chemokine levels, serum and colonic sections were 
isolated from experimental and control mice. Blood was centrifuged at 2,500 rpm at 4°C for 
5 minutes, and the separated serum was collected. 30 mg of colonic tissue was homogenized 
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in 0.5 mL of PBS buffer containing 0.1% Tween 20 with protease inhibitors. Tissue 
homogenates were then centrifuged at 14,000 rpm for 10 minutes at 4°C to pellet debris, and 
the supernatant was used for cytokine/chemokine detection. The levels of cytokines and 
chemokines were detected in the serum using a Milliplex Mouse Cytokine/Chemokine 
Immunoassay (Millipore) per the manufacturer’s instructions. The assay included reagents 
to measure the following: Eotaxin, G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β;, IL-2, IL-3, IL-4, 
IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IP-10, LIF, LIX, 
MCP-1, M-CSF, MIG, MIP-1β;, MIP-1α, MIP-2, RANTES, TNFα, and VEGF. The 
Milliplex protocol was altered for the colonic tissue, substituting the provided matrix 
solution with the buffer used for colonic homogenization. All samples were analyzed in 
triplicate with detection and analysis performed on a on a Bio-Plex 200 detection system 
(Bio-Rad).
Human Clinical Samples
Following institutional review board (IRB) review and approval, normal and cancerous 
colonic tissue was obtained as frozen samples and paraffin-embedded sections from the 
Tissue Procurement Facility at the University of North Carolina at Chapel Hill and Poudre 
Valley Hospital (Fort Collins, CO) in collaboration with Colorado State University. Each 
specimen was distributed with a unique identification number (no patient identifying 
information was distributed) in accordance with patient privacy and confidentiality 
guidelines.
Statistics
Supplementary Table S3 lists the statistical test used for each figure. In experiments where a 
hypothesis was tested by comparing 2 groups of samples, a two-tailed t test was used to 
determine significant differences. For more than 2 groups of samples, ANOVA followed by 
a Tukey post-hoc test was used. In experiments where the data did not follow a normal 
distribution, a Kruskal-Wallis non-parametric statistical test was used. It was used instead of 
a Mann-Whitney test because more than 2 groups of samples were compared in our 
experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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These results, which link diet and microbiota to a tumor-suppressive metabolite, provide 
insight into conflicting epidemiologic findings and suggest that probiotic/prebiotic 
strategies can modulate an endogenous HDAC inhibitor for anticancer chemoprevention 
without the adverse effects associated with synthetic HDAC inhibitors used in 
chemotherapy.
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A high-fiber diet protects against colorectal tumors in a microbiota- and butyrate-dependent 
manner. (A, B) Scatter plots showing tumor multiplicity for mice in each treatment group 
following low (A) and high (B) carcinogen exposures. Means are shown, and symbols 
denote groups with statistically-significant differences: * versus #, p < 0.01; * versus +, p = 
0.05; # versus +, p < 0.05. (C) Tumor size presented as mean ± SE with significant 
differences indicated (* versus #, p < 0.01). (D) Percentage of low-grade versus high-grade 
tumors for each treatment group based on H&E characteristics of dysplasia within tumors as 
described in panel E. (E) H&E-stained sections representative of normal colonic epithelium, 
low-grade tumors, and high-grade tumors. Compared to normal colon, low-grade tumors 
exhibit hyperplasia (circled region) and are less differentiated with fewer goblet cells that 
are identified by mucous vacuoles (black dot). High-grade tumors exhibit these features plus 
a loss of polarity (dotted circled region) and have crypt abscesses with apoptotic material 
(star). A subset of high-grade tumors display signs of potential invasion based on tumor cells 
within the muscularis (inset).
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Colorectal tumors exhibit characteristics of the Warburg effect, accumulate butyrate, and 
have increased H3ac levels. (A) Representative western blot of LDHA in normal colonic 
tissue and a colorectal tumor. β-actin serves as a loading control. (B) Quantification of 
LDHA levels normalized to β-actin in normal colonic tissues and tumors based on western 
blot data. Each histogram shows the mean ± SE based on 3 biological replicates (i.e. colonic 
tissue and tumors from 3 separate mice) with significant differences indicated (*, p < 0.05). 
(C) Lactate levels in normal colonic tissue and colorectal tumors based on LC-MS 
measurements. Results are normalized to μg of protein, and each histogram shows the mean 
± SE of 4-5 biological replicates (i.e. colonic tissue and tumors from 4-5 separate mice) with 
significant differences indicated (*, p < 0.05). (D) Representative LC-MS chromatograms 
showing butyrate levels in normal colonic tissue and a colorectal tumor. (E) Butyrate levels 
in normal colonic tissues and tumors from mice in control and experimental treatment 
groups. Values are based on LC-MS measurements, and each histogram shows the mean ± 
SE of 5 biological replicates (i.e. colonic tissue and tumors from 5 separate mice) with 
significant differences indicated (*, p < 0.05; **, p < 0.01). (F) Representative IHC image 
showing H3ac staining intensity in tumor cells and adjacent normal colonic epithelial cells. 
(G) Western blot analysis of H3ac and total H3 levels in tumors from mice of the different 
treatment groups. (H) Quantification of western blot data with H3ac levels normalized to 
total H3 in tumors from mice of each treatment group. LFD, low-fiber diet; HFD, high-fiber 
diet. Each histogram shows the mean ± SE based on 5 biological replicates for each 
treatment group with significant differences indicated (*, p < 0.05; **, p < 0.01). (I) HDAC 
activity levels normalized to protein levels in normal colonic tissue and tumors from control 
and experimental treatment groups. Each histogram shows the mean ± SE for 5 independent 
experiments with significant differences indicated (*, p < 0.05; **, p < 0.01).
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Tumors from mice provided a high-fiber diet and colonized with B. fibrisolvens 
(experimental treatment group) have increased H3ac and expression levels of target genes 
and undergo increased apoptosis and decreased cell proliferation. (A,C,E) Quantitative ChIP 
assays showing H3ac enrichment at the promoters of the Fas, p21, and p27 genes in normal 
colonic tissues and tumors as indicated. qPCR results for each ChIP were normalized to 
input, and the values of normal colonic tissues from control mice were set at 1.0. Each 
histogram shows the mean ± SE for 3-4 independent experiments with significant 
differences indicated (*, p < 0.05; **, p < 0.01). (B,D,F) RT-qPCR analysis of Fas, p21, and 
p27 mRNA levels normalized to Gapdh levels in normal colonic tissues and tumors. The 
values of normal colonic tissues from control mice were set at 1.0. Each histogram shows 
the mean ± SE for 5 independent experiments with significant differences indicated (*, p < 
0.05; **, p < 0.01). (G) Quantification of cleaved caspase 3 positive cells in normal colonic 
epithelial cells and tumors from the control and experimental treatment groups. Each 
histogram shows the mean ± SE based on 10 biological replicates for each group with 
significant differences indicated (*, p < 0.05; **, p < 0.01). (H) Quantification of Ki-67 
levels in normal colonic epithelial cells and tumors from the control and experimental 
treatment groups. The values of normal colonic tissues from control mice were set at 1.0. 
Each histogram shows the mean ± SE based on 10 biological replicates for each group with 
significant differences indicated (*, p < 0.05).
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A model depicting the mechanism of the fiber-microbiota-butyrate axis in tumor suppression 
and evidence to support the relevance of this model to human cancer prevention. (A- D) 
Relevance of the model to human cancer. (A) Butyrate levels in macroscopically normal 
colonic tissue and colorectal adenocarcinomas from humans based on LC-MS 
measurements. Each histogram shows the mean ± SE from 11 biological replicates of each 
with significant differences indicated (*, p < 0.05). (B) A scatter plot of the samples from 
panel A. The samples were obtained from the University of North Carolina at Chapel Hill 
(white, left) and Colorado State University (black, right) tissue procurement facilities. (C) 
Western blot analysis of H3ac and total H3 levels in macroscopically normal colonic tissue 
and colorectal adenocarcinomas from 2 pairs of human samples. (D) Quantification of 
western blot data with H3ac levels normalized to total H3 in macroscopically normal colonic 
tissue and colorectal adenocarcinomas. Each histogram shows the mean ± SE from 5 
biological replicates of each with significant differences indicated (*, p < 0.05). (E) Final 
working model.Dietary fiber is fermented by microbiota into butyrate, which is a short-chain 
fatty acid that is abundant (mM levels) in the lumen of the colon. In normal colonocytes, 
butyrate undergoes oxidative metabolism in the mitochondria to promote homeostasis. In the 
cancerous colonocyte, due to the Warburg effect, butyrate is metabolized to a lesser extent 
and accumulates in the nucleus where it functions as an HDAC inhibitor to induce apoptosis 
and inhibit cell proliferation. The importance of the Warburg effect in this model draws 
upon previous work (22). In addition to these cell-autonomous effects within the cancer cell, 
some of the tumor suppression could be mediated by butyrate promoting Treg cell 
differentiation and having anti-inflammatory effects in the presence of a complex gut 
microbiota.
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